Tiltan Pharma   Report issue

For profit Phase 2
Founded: Jerusalem Israel (2006)
Status: No NME R&D (2006)

Organization Overview

First Clinical Trial
2009
NCT00684970
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Alternative names

Chief Operating Officer, Tiltan Pharma LtD | Tiltan Pharma Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Pancreatic Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 5